Haleon (LON:HLN) Stock Price Target Lowered at Berenberg Bank

Haleon (LON:HLN) had its price objective lowered by stock analysts at Berenberg Bank from GBX 514 to GBX 365 in a report released on Monday, Digital Look reports. The firm presently has a “buy” rating on the stock. Berenberg Bank‘s target price would indicate a potential upside of 14.87% from the stock’s current price.

Several other research analysts have also commented on the company. Royal Bank Of Canada lifted their price target on Haleon from GBX 370 to GBX 390 and gave the stock a “sector perform” rating in a report on Tuesday, August 11th. Deutsche Bank Aktiengesellschaft raised shares of Haleon to a “hold” rating and dropped their price objective for the company from GBX 320 to GBX 310 in a report on Friday. Finally, Jefferies Financial Group restated a “buy” rating and set a GBX 400 price objective on shares of Haleon in a research report on Friday. Two analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of GBX 356.

Haleon Stock Performance

Shares of Haleon stock opened at GBX 317.75 on Monday. The business’s 50 day moving average price is GBX 352.97 and its 200 day moving average price is GBX 360.40. The company has a market cap of £27.95 billion, a price-to-earnings ratio of 17.56, a PEG ratio of 1.49 and a beta of 0.24. The company has a debt-to-equity ratio of 50.38, a quick ratio of 0.93 and a current ratio of 0.69. Haleon has a one year low of GBX 310.50 and a one year high of GBX 433.60.

Haleon (LON:HLN) last issued its earnings results on Thursday, July 30th. The company reported GBX 8.60 earnings per share (EPS) for the quarter. Haleon had a return on equity of 9.89% and a net margin of 14.55%. On average, research analysts predict that Haleon will post 19.50 EPS for the current year.

Haleon declared that its board has authorized a share repurchase program on Thursday, October 29th that allows the company to repurchase £500 million in shares. This buyback authorization allows the company to buy up to 1.8% of its stock through open market purchases. Stock buyback programs are often an indication that the company’s management believes its shares are undervalued.

Key Headlines Impacting Haleon

Here are the key news stories impacting Haleon this week:

• Positive Sentiment: Haleon approved a £500 million share repurchase program, equivalent to as much as 1.8% of outstanding shares. The buyback could support earnings per share and signals that management views the shares as undervalued. Haleon Q3 Revenue Rises; Trims Annual Revenue Growth Outlook; Launches £500 Mln Share Buyback
• Positive Sentiment: Jefferies reaffirmed its buy rating and set a GBX 400 price target, implying substantial upside from recent trading levels and providing some support for the stock. Jefferies reaffirms Haleon buy rating
• Neutral Sentiment: Deutsche Bank upgraded Haleon to hold but reduced its price target to GBX 310 from GBX 320. The change reflects a more balanced view rather than a strongly bullish signal. Deutsche Bank Haleon rating update
• Neutral Sentiment: Institutional positioning was mixed, with some major investors adding Haleon shares while others reduced holdings. These moves may influence sentiment but do not establish a clear near-term direction.
• Negative Sentiment: Haleon reported third-quarter organic revenue growth of 2.6%, below expectations, and cut its 2026 organic revenue growth outlook to about 2.5% from a previous 3%–5% range. Weak cough, cold and flu demand in North America, disruption to Centrum products in China, and a planned Brazil go-to-market change contributed to the downgrade. Haleon drops after Q3 sales miss and lower 2026 growth outlook

Haleon Company Profile

Haleon (LSE / NYSE: HLN) is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges.

Haleon’s product portfolio spans six major categories – Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands – such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren – are built on trusted science, innovation and deep human understanding.